These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 21857923)

  • 21. The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.
    Cresto N; Gaillard MC; Gardier C; Gubinelli F; Diguet E; Bellet D; Legroux L; Mitja J; Auregan G; Guillermier M; Josephine C; Jan C; Dufour N; Joliot A; Hantraye P; Bonvento G; Déglon N; Bemelmans AP; Cambon K; Liot G; Brouillet E
    Neurobiol Dis; 2020 Feb; 134():104614. PubMed ID: 31605779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation.
    Bae EJ; Kim DK; Kim C; Mante M; Adame A; Rockenstein E; Ulusoy A; Klinkenberg M; Jeong GR; Bae JR; Lee C; Lee HJ; Lee BD; Di Monte DA; Masliah E; Lee SJ
    Nat Commun; 2018 Aug; 9(1):3465. PubMed ID: 30150626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease.
    Vitte J; Traver S; Maués De Paula A; Lesage S; Rovelli G; Corti O; Duyckaerts C; Brice A
    J Neuropathol Exp Neurol; 2010 Sep; 69(9):959-72. PubMed ID: 20720502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans.
    Saha S; Guillily MD; Ferree A; Lanceta J; Chan D; Ghosh J; Hsu CH; Segal L; Raghavan K; Matsumoto K; Hisamoto N; Kuwahara T; Iwatsubo T; Moore L; Goldstein L; Cookson M; Wolozin B
    J Neurosci; 2009 Jul; 29(29):9210-8. PubMed ID: 19625511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
    Lin CH; Lin HI; Chen ML; Lai TT; Cao LP; Farrer MJ; Wu RM; Chien CT
    Hum Mol Genet; 2016 May; 25(10):1965-1978. PubMed ID: 26931464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modelling the functional genomics of Parkinson's disease in Caenorhabditis elegans: LRRK2 and beyond.
    Chandler RJ; Cogo S; Lewis PA; Kevei E
    Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34397087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Human LRRK2 in Methylmercury-Induced Inhibition of Microvesicle Formation of Cephalic Neurons in Caenorhabditis elegans.
    Ke T; Santamaria A; Rocha JBT; Tinkov AA; Lu R; Bowman AB; Aschner M
    Neurotox Res; 2020 Oct; 38(3):751-764. PubMed ID: 32725544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice.
    Xiong Y; Neifert S; Karuppagounder SS; Liu Q; Stankowski JN; Lee BD; Ko HS; Lee Y; Grima JC; Mao X; Jiang H; Kang SU; Swing DA; Iacovitti L; Tessarollo L; Dawson TM; Dawson VL
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1635-1640. PubMed ID: 29386392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Valproic acid ameliorates C. elegans dopaminergic neurodegeneration with implications for ERK-MAPK signaling.
    Kautu BB; Carrasquilla A; Hicks ML; Caldwell KA; Caldwell GA
    Neurosci Lett; 2013 Apr; 541():116-9. PubMed ID: 23485787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. (R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model.
    Weng YH; Chen CY; Lin KJ; Chen YL; Yeh TH; Hsiao IT; Chen IJ; Lu CS; Wang HL
    Exp Neurol; 2016 Jan; 275 Pt 1():104-15. PubMed ID: 26363496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Caenorhabditis elegans AKT-1/2 and SGK-1 in Manganese Toxicity.
    Peres TV; Arantes LP; Miah MR; Bornhorst J; Schwerdtle T; Bowman AB; Leal RB; Aschner M
    Neurotox Res; 2018 Oct; 34(3):584-596. PubMed ID: 29882004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Molecular basis of Parkinson's disease linked with mutations in the LRRK2 gene].
    Pchelina SN; emel'ianov AK; Usenko TS
    Mol Biol (Mosk); 2014; 48(1):3-14. PubMed ID: 25842821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration.
    Jeong GR; Jang EH; Bae JR; Jun S; Kang HC; Park CH; Shin JH; Yamamoto Y; Tanaka-Yamamoto K; Dawson VL; Dawson TM; Hur EM; Lee BD
    Mol Neurodegener; 2018 Feb; 13(1):8. PubMed ID: 29439717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parkinson's disease-associated LRRK2-G2019S mutant acts through regulation of SERCA activity to control ER stress in astrocytes.
    Lee JH; Han JH; Kim H; Park SM; Joe EH; Jou I
    Acta Neuropathol Commun; 2019 May; 7(1):68. PubMed ID: 31046837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.
    Cho HJ; Liu G; Jin SM; Parisiadou L; Xie C; Yu J; Sun L; Ma B; Ding J; Vancraenenbroeck R; Lobbestael E; Baekelandt V; Taymans JM; He P; Troncoso JC; Shen Y; Cai H
    Hum Mol Genet; 2013 Feb; 22(3):608-20. PubMed ID: 23125283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LRRK2 Gly2019Ser Mutation Promotes ER Stress via Interacting with THBS1/TGF-β1 in Parkinson's Disease.
    Yao L; Lu F; Koc S; Zheng Z; Wang B; Zhang S; Skutella T; Lu G
    Adv Sci (Weinh); 2023 Oct; 10(30):e2303711. PubMed ID: 37672887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigating convergent actions of genes linked to familial Parkinson's disease.
    Wolozin B; Saha S; Guillily M; Ferree A; Riley M
    Neurodegener Dis; 2008; 5(3-4):182-5. PubMed ID: 18322385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.
    Skibinski G; Nakamura K; Cookson MR; Finkbeiner S
    J Neurosci; 2014 Jan; 34(2):418-33. PubMed ID: 24403142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NME1 Protects Against Neurotoxin-, α-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson's Disease.
    Anantha J; Goulding SR; Tuboly E; O'Mahony AG; Moloney GM; Lomansey G; McCarthy CM; Collins LM; Sullivan AM; O'Keeffe GW
    Mol Neurobiol; 2022 Jan; 59(1):61-76. PubMed ID: 34623600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.